TCL Archive Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer July 31, 2009
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive Cancer Control Program Guidelines Developed For Payment Of Patient Costs December 21, 1973
